Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Nasopharyngeal Carcinoma 2Triple Negative Breast Neoplasms 1Recurrence 1Rectal Neoplasms 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Bevacizumab 11durvalumab 9atezolizumab 9Specimen Handling 9tremelimumab 8lenvatinib 7Nivolumab 6Magnetic Resonance Spectroscopy 5X-Rays 4Sorafenib 3Oxaliplatin 3Ipilimumab 3Fluorouracil 3tislelizumab 2sapanisertib 2relatlimab 2cabozantinib 2Surgical Procedures, Operative 2Radiation 2Leucovorin 2Immunotherapy 2Immunoglobulin G 2Doxorubicin 2Disulfides 2Carboplatin 2ulixertinib 1trifluridine tipiracil drug combination 1trastuzumab biosimilar HLX02 1trametinib 1sofosbuvir-velpatasvir drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × sintilimab × 30 days × Clear all
NCT07584018 2026-05-13

The DoHAICs Study Expansion Phase

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
90 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡